{"id":"azt-3tc-abv-trizivir","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":"5-8","effect":"Abacavir hypersensitivity reaction"},{"rate":null,"effect":"Lipoatrophy"},{"rate":null,"effect":"Lactic acidosis"}]},"_chembl":{"chemblId":"CHEMBL178240","moleculeType":"Small molecule","molecularWeight":"267.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AZT (zidovudine), 3TC (lamivudine), and ABV (abacavir) are all NRTIs that inhibit HIV reverse transcriptase by competing with natural nucleotides and causing chain termination during viral DNA synthesis. This combination provides synergistic antiretroviral activity against HIV-1 by targeting the same enzyme through multiple mechanisms, reducing the likelihood of resistance development compared to monotherapy.","oneSentence":"Trizivir is a fixed-dose combination of three nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase to prevent viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:26.996Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT00865475","phase":"PHASE4","title":"Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2008-12","conditions":"HIV Infection, HIV Infections","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":47,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LPV/r (Kaletra)"],"phase":"marketed","status":"active","brandName":"AZT+3TC+ABV (Trizivir)","genericName":"AZT+3TC+ABV (Trizivir)","companyName":"Fundacion SEIMC-GESIDA","companyId":"fundacion-seimc-gesida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trizivir is a fixed-dose combination of three nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}